GlobeNewswire by notified

Ensurge successfully completed first phase of building Multi-Layered Batteries of its Rechargeable Solid-State Lithium Microbattery

Share

SAN JOSE, Calif., September 14, 2023 -- Ensurge Micropower (OSE: ENSU, and OTCQB: ENMPY) (“Ensurge” or the “Company”), today announces to have successfully completed the first phase of building multi-layered solid-state lithium micro battery with predefined capabilities. Based on this important milestone, the Company’s lead customer within the digital health market has decided to commence product testing. 

The digital-health market innovator has already in 2022 evaluated the Company’s unit-cell and package single-layer samples, which in December 2022 led to a 150,000-unit order for Ensurge’s rechargeable 1-100 milliampere-hour (mAh) microbattery. The order will be delivered when entering volume production. 

"We continue to work closely with our lead customer through each stage of our microbattery’s development,” said Lars Eikeland, CEO at Ensurge. “In earlier tests we have already validated its improved charging speed, high pulse discharge and other benefits that are critically important for digital health, fitness, and remote patient monitoring applications.”  

The cooperation between Ensurge and the lead customer contemplates bringing this novel battery technology into full production in 2023. Further optimization and improvements will allow necessary capacity enhancements allowing game-changing competitiveness for lead customers devices. 

Other customers and technology partners will receive batteries for testing for the current version of the multilayer solid-state battery over the coming weeks.

Click  https://youtu.be/6Sc7SZFVRmc to see a video demonstration of Ensurge’s multilayer core-sell stacking functionality using surface-mounted microbatteries that have been assembled onto demonstration boards.

About Ensurge Micropower
Ensurge is Energizing Innovation™ with the first ultrathin, flexible, reliable, and fundamentally safe solid-state lithium microbattery for the 1 to 100 milliampere-hour (mAh) class of wearable devices, connected sensors, and beyond. The innovative Ensurge Microbattery enables energy-dense rechargeable products that are ideal for form-factor-constrained applications including hearables (hearing aids and wireless headphones), digital and health wearables, sports, and fitness devices, as well as IoT-connected device solutions using energy harvesting to power everyday things. The Company's state-of-the-art manufacturing facility, located in the heart of Silicon Valley, combines patented process technology and materials innovation with the scale of roll-to-roll production methods to bring the advantages of Ensurge technology to established and expanding markets.

This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Contact 
Investor Relations 
E-mail: IR@ensurge.com

Lars Eikeland - Chief Executive Officer 
E-mail: lars.eikeland@ensurge.com

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

SkiStar Year-End Report September 2022-August 20233.10.2023 07:00:00 CEST | Press release

STABLE GROWTH IN TURNOVER – HIGH BOOKING RATE FOR THE WINTER Fourth Quarter Net sales for the fourth quarter increased by SEK 121 million (54 percent) to SEK 345 (224) million.Operating profit for the fourth quarter amounted to SEK -230 (-265) million, an improvement of SEK 35 million (13 percent).Capital gains from exploitation operations included SEK 63 (-4) million.Earnings per share before and after dilution amounted to SEK -2.64 (-2.70). Full Year Net sales for the full year were SEK 4,281 (4,092) million, an increase of SEK 189 million (5 percent).Operating profit for the full year decreased by SEK 280 million (32 percent) to SEK 604 (884) million.Earnings per share before and after dilution amounted to SEK 5.13 (8.50), a decrease of 40 percent.Capital gains from Property Development and Exploitation operations included SEK 75 (57) million.The Board proposes a dividend of SEK 2.60 (3.00) per share, totalling SEK 204 (235) million. The dividend represents 51 (36) percent of the Gr

NMD Pharma to present NMD670 clinical data from a Phase I/IIa trial in myasthenia gravis at the 28th International Annual Congress of the World Muscle Society3.10.2023 07:00:00 CEST | Press release

NMD Pharma to present NMD670 clinical data from a Phase I/IIa trial in myasthenia gravis at the 28th International Annual Congress of the World Muscle Society NMD Pharma will show the first ever clinical proof-of-mechanism for the novel concept of ClC-1 inhibition with NMD670 in treatment of neuromuscular diseases demonstrated in patients with myasthenia gravis The data provides clinical validation of the ability of CIC-1 inhibition to restore neuromuscular function leading to clinically meaningful effects with a single dose of NMD670This data has been instrumental in the design ofthe recently initiated Phase II clinical trial of NMD670 in patients with type 3 spinal muscular atrophy Aarhus, Denmark,3October2023 – NMD Pharma A/S, a clinical-stage biotech company developing first-in-class, small molecule ClC-1 inhibitors directly targeting muscle function within neuromuscular disorders, today announces that it will present data from a Phase I/IIa clinical trial of NMD670 in patients wit

“BEYOND THE EXPECTED”: SIKA LAUNCHES NEW GROWTH STRATEGY 2028 WITH MORE AMBITIOUS TARGETS3.10.2023 07:00:00 CEST | Press release

Ad Hoc Announcement Pursuant to Article 53 of the SIX Exchange Regulation Listing Rules “BEYOND THE EXPECTED”: SIKA LAUNCHES NEW GROWTH STRATEGY 2028 WITH MORE AMBITIOUS TARGETS At today’s Capital Markets Day in Zurich, Sika presents its new Strategy 2028, “Beyond the Expected”, which builds on the company’s successful growth model. The roadmap leverages on Sika’s strong market position and innovation power and sets the course for an even stronger performance in the years to come. The annual growth target will be lifted to 6-9% in local currencies and profitability target will be increased to an EBITDA margin of 20-23%. The new growth strategy is based on the four pillars market penetration, innovation & sustainability, acquisitions, as well as people & culture and includes a balanced set of financial and non-financial targets. Furthermore, Sika reports a strong sales growth year to date (January to August 2023) of +12.2%. Thomas Hasler, CEO: “Beyond the Expected – that’s what Sika sta

SkiStar Bokslutskommuniké september 2022-augusti 20233.10.2023 07:00:00 CEST | Pressemelding

STABIL OMSÄTTNINGSTILLVÄXT – HÖGT BOKNINGSLÄGE TILL VINTERN Fjärde kvartalet Nettoomsättningen för det fjärde kvartalet ökade med 121 MSEK, 54 procent, till 345 MSEK (224).Rörelseresultatet för det fjärde kvartalet uppgick till -230 MSEK (-265), vilket är en förbättring med 35 MSEK, 13 procent.Reavinster från exploateringsverksamheten ingick med 63 MSEK (-4).Resultat per aktie före och efter utspädning uppgick till -2,64 SEK (-2,70). Helåret Nettoomsättningen för helåret ökade med 189 MSEK, 5 procent, till 4 281 MSEK (4 092).Rörelseresultatet för helåret minskade med 280 MSEK, 32 procent, till 604 MSEK (884).Resultat per aktie före och efter utspädning uppgick till 5,13 SEK (8,50), vilket är en minskning med 40 procent.Reavinster från Fastighetsutvecklings- och exploateringsverksamheten ingick med 75 MSEK (57).Styrelsen föreslår en vinstutdelning om 2:60 SEK (3:00) per aktie, motsvarande totalt 204 MSEK (235). Utdelningen utgör 51 procent (36) av koncernens vinst efter skatt. Väsentlig

Technicolor Creative Studios: Business Update and First Half 2023 Financial Results2.10.2023 21:55:38 CEST | Press release

CORPORATE PRESS RELEASE Technicolor Creative StudiosBusiness Update and First Half 2023Financial Results PARIS (FRANCE), OCTOBER 2,2023 – Technicolor Creative Studios (Euronext Paris: TCHCS) (the “Company”) today provided business update and announced its first half 2023 financial results1. Acceleration of the transformation plan to drive the recovery of the business Impact of strikes in Hollywood andunfavourable macroeconomic environment led to reduction of activity withlower financial and operational performancefor thefirst half 2023Renewed confidence from majority shareholders and lenders with:An additional €30 million of new money injection to address liquidity needs A proposed tender offer (“offre publique d’achat simplifiée”)at a price of 1,63 euro per share, dividends included,to beinitiated by a large majority of shareholders and lenders (holding 94,82% of the capital) acting in concert in view of proceeding to a mandatory squeeze outto achieve delisting of Technicolor Creative